2Sieradzan KA,Mann DM.The selective vulnerability of nerve cells in Huntington's disease.Neuropathol Appl Neurobiol,2001,27(1):1-21.
3Ferrer I,Blanco R,Cutillas B,et al.Fas and Fas-L expression in Huntington's disease and Parkinson's disease.Neuropathol Appl Neurobiol,2000,26 (5):424-433.
4Gafni J,Ellerby LM.Calpain activation in Huntington 's disease.J Neurosci.,2002,22(12):4842-4849.
5Hermel E,Gafni J,Propp SS,et al.Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.Cell Death Differ,2004,11(4):424-438.
6Vis JC,Schipper E,Roelie T,et al.Expression pattern of apoptosis-related markers in Huntington's disease.Acta Neuropathol,2005,109(3):321-328.
7Antonawich FJ,Fiore-Marasa SM,Parker CP.Modulation of apoptotic regulatory proteins and early activation of cytochrome C following systemic 3-nitropropionic acid administration.Brain Res Bull,2002,57(5):647-649.
8Turmaine M,Raza A,Mahal A.Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease.Proc Natl Acad Sci U S A,2000,97 (14):8093-8097.
9de Almeida LP,Ross CA,Zala D,et al.Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size,huntingtin expression levels,and protein length.J Neurosci,2002,22(9):3473-3483.
10Menalled LB,Sison JD,Wu Y,et al.Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice.J Neurosci,2002,22(18):8266-8276.
